04 Feb 2021 | News
Viewpoint: Lessons from Operation Warp Speed can help overcome EU vaccines crisis
As the problem of COVID-19 vaccines supplies so potently illustrates, it is time to rethink the EU’s pandemic preparedness strategy. More support is needed for late stage clinical development and large scale manufacturing
Michel Goldman, former executive director of the EU Innovative Medicines Initiative and professor emeritus at the Université Libre de Bruxelles.
Despite European Medicines Agency approval of three COVID-19 vaccines and the hundreds of millions of doses procured through advance purchase agreements negotiated by the European Commission, member states are facing a shortage of vaccine supplies and falling behind Israel, the UK and the US in terms of vaccines coverage.
DGAP-News: Imcys .
DGAP-News: Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
vom 03.02.2021, 14:00 Uhr
Bild: pixabay.com
DGAP-News: Imcyse SA / Key word(s): Study
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
03.02.2021 / 14:00
The issuer is solely responsible for the content of this announcement.
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
Liège, Belgium, February 03, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients treatment in the
03 febbraio 2021 12:02
Fonte: Adnkronos
#salute-e-benessere
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.
The clinical development of engineered T-cell treatments is moving ahead and the EU has already approved this therapy for the treatment of leukemia. Despite its potential to cure many types of cancers and other infectious or autoimmune diseases, the translation into clinical trials and entry into the EU market is slow and lagging behind o
Press release content from Accesswire. The AP news staff was not involved in its creation.
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
February 3, 2021 GMT
LIEGE, BELGIUM / ACCESSWIRE / February 3, 2021 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients’ treatment in the IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT) study with IMCY-0098. The IMPACT trial, in collaboration with INNODIA, will evaluate the ability of the ImotopeTM IMCY-0098 to preserve beta-cell function in adult and adolescent patients with recent onset T1D as well as determine the best and safe dose and regimen for continued development. Patient recruitment is ongoing. Topline data from the study is anticipated in the second half of 2023.
It looks like this was the result of either:
A mistyped address
A broken link on our site
A broken link on a search engine results page
A broken link on someone else s page
Some things to try:
Use the navigation menu at the top Most Read